[lou_lou]

http://www.goldstandard.com/

Gold Standard is delighted to work together with Therapeutic Research Center, publisher of Pharmacist's Letter and Natural Medicines Comprehensive Database, to offer our customers quick and easy access to exceptional, integrated drug information content, enhanced functionality and even greater value!

Institutions that subscribe to Clinical Pharmacology and Pharmacist's Letter and/or Natural Medicines Comprehensive Database will be able to conveniently access any one of these resources and link directly to relevant information in all three - there's no additional cost or IT work required.

Pharmacist's Letter covers new developments in drug therapy and trends in pharmacy practice, with the latest recommendations and comparisons based on new studies, warnings and guidelines. Natural Medicines Comprehensive Database provides a database of all natural ingredients and all brand name natural products with ratings on safety, efficacy and product quality.

As a Clinical Pharmacology subscriber, if you already subscribe to Pharmacist's Letter and/or Natural Medicines Comprehensive Database, simply contact Gold Standard today at 800-375-0943 or sales@goldstandard.com to activate the links for your pharmacies.

For more information about subscribing to Pharmacist's Letter and/or Natural Medicines Comprehensive Database, please visit Therapeutic Research Center at

http://www.therapeuticresearch.com/cp
or contact Becky Thornburg at 209-472-2240, Ext. 237 or bthornburg@pletter.com.

For site license pricing, please call 1-800-375-0943 or 813-258-4747, or email sales@goldstandard.com.

I looked up PD meds and found how they make gold...
http://tinyurl.com/a9mnuu

[lou_lou]

New drugs from old
The NHS spends over £10 billion each year on medicines.1 The use of generic (patent-expired) medicines rather than branded equivalents has a key role in containing this expenditure and ensuring best value for money. On average, 4 years after the patent of a branded medicine has expired in the UK, generic equivalents will account for around half of the drug's market and cost about a quarter as much as the original brand.1,2
This represents a potentially large loss of income and, therefore, a major concern for companies that market branded products.3 Consequently, many use a long-term strategy known as 'lifecycle management' to minimise loss and to maximise returns from such products.2,4
This encompasses prioritising products for development, forming strategic alliances with other companies to share resourses, and utilising legal processes to protect products. One part of this strategy is the development and intensive marketing of new formulations or derivatives of existing medicines nearing the end of their patent life. Here we highlight some key examples of the impact the marketing of such products can have on patients, prescribers and the NHS

http://dtb.bmj.com/cgi/content/abstract/44/10/73
and this link
http://www.ftc.gov/be/v990016.shtm

[bandido1]

Nothing surprising here! To quote a frequently seen sign on the street:
THE END IS COMING!! AKA NATIONAL HEALTHCARE REFORM. Bob C